Back to search results

Magnetic Flexible Endoscope (MFE) for Inflammatory Bowel Disease (IBD) Colonoscopy

This study is testing a new device called the Magnetic Flexible Endoscope (MFE) for colon exams in people with Inflammatory Bowel Disease (IBD). The MFE is a very flexible tube with a camera and a magnet at its tip. A robotic arm outside your body uses another magnet to gently guide the MFE through your colon. This aims to make colonoscopies less uncomfortable and risky than standard procedures. Researchers want to see if the MFE can successfully reach the end of the colon (cecum) in IBD patients. This study is looking for 6 participants between 18 and 70 years old who have stable IBD and no major health problems. The current recruitment status is unclear.

Study design
This is an interventional study with 6 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo a procedure with the Magnetic Flexible Endoscope (MFE). The study aims to see how the MFE travels through your colon and if it is tolerable.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured at Day 1, which suggests a short follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06989424

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD)

Not Yet Recruiting
NAAges 18–70InterventionalDevice feasibility
Vanderbilt University Medical Center
~6 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Magnetic Flexible Endoscope (MFE)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility to intubate the cecum (yes/no)
Measured over Day 1

Conditions

Inflammatory Bowel Disease (IBD)
Colonoscopy

Explore related trials

Inflammatory Bowel Disease

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Keith L Obstein · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Who to contact

Michael G McGill
[email protected]
615-322-4643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female, 18 to 70 years of age
Able to provide written informed consent
American Society of Anesthesiologists (ASA) class \< 3
No significant medical problems
Abdominal circumference \< 96 cm
Stable, non-flaring inflammatory bowel disease (e.g. Ulcerative Colitis and Crohn's Disease)
Patients who are unable or unwilling to provide informed consent
Magnetic implants and wearable devices (such as insulin pumps)
Females who are pregnant. As part of routine pre-operative care, all females of childbearing potential will undergo either urine or blood pregnancy testing.
Cancer positive subjects or any patients currently undergoing any treatment or therapy to treat, cure, or mitigate cancer.
Symptoms consistent with coronavirus (COVID-19) --- pyrexia, new persistent cough, or anosmia --- or a positive coronavirus (COVID-19) polymerase chain reaction (PCR) swab result
Previous incomplete or failed colonoscopy
Colonic resection
Severe diverticulosis
Known or suspected colonic stricture
Previous radiation therapy to the abdomen or pelvis
Actively flaring inflammatory bowel condition (e.g. active flare of IBD or diverticulitis)
Known or suspected bowel obstruction
Presence of ascites
Participants taking anticoagulant medications or antiplatelet therapy (excluding aspirin) within the last 3 days
Known coagulation disorder (INR ≥ 1.5 or platelets \< 150 x 109)
Known to have phenylketonuria or Glucose-6-Phosphate-Dehydrogenase (G6PD) deficiency
Abdominal surgery within the last 6 months
Drug or alcohol abuse

What this trial measures

  • Feasibility to intubate the cecum (yes/no)Day 1

    Ability to feasibly enter the cecum of the colon. Will be confirmed per standard endoscopic practice of visualizing and photo documenting at least 2 of the 3 common cecum landmarks (ileocecal valve, triradiate fold, appendiceal orifice).